T cell receptor specific for Plasmodium falciparum peptide–MHC complexes (Pf-TCR)

The T cell receptor (TCR) specific for Plasmodium falciparum peptide–MHC complexes is a fundamental mediator of the adaptive immune response against malaria (NIH, 2024). These receptors, expressed on the surface of CD8+ and CD4+ T cells, recognize specific parasite antigens—such as the circumsporozoite protein (CSP) or apical membrane antigen 1 (AMA1)—presented by Major Histocompatibility Complex (MHC) molecules on infected hepatocytes or antigen-presenting cells (Frontiers in Immunology, 2024). This recognition event triggers T cell activation, leading to the production of protective cytokines like interferon-gamma (IFN-gamma) and the direct killing of infected cells, which is crucial for achieving sterile protection and controlling parasite burden (MDPI, 2025). In the pharmaceutical landscape, these TCRs are the primary targets for vaccine-induced immunity, with candidates like RTS,S/AS01 and R21/Matrix-M designed to elicit robust TCR-mediated responses (Nature, 2025). Furthermore, emerging strategies such as TCR-T cell therapy and the use of immune checkpoint inhibitors (e.g., anti-PD-1) aim to modulate these receptors to overcome parasite-induced immune exhaustion and enhance therapeutic outcomes (MalariaWorld, 2025). However, the high genetic diversity of P. falciparum and the risk of off-target toxicity or hyper-inflammatory responses remain significant hurdles in targeting these receptors effectively. Understanding the structural basis of TCR-pMHC interactions is also vital for identifying conserved epitopes that can provide strain-transcending immunity (bioRxiv, 2026). Overall, these receptors represent a cornerstone of both natural and vaccine-induced protection against the world's most deadly malaria parasite.

Other names

Malaria-specific T-cell receptorPlasmodium-specific TCRTCR-pMHC (Pf)Plasmodium falciparum-specific T-cell receptor

Vaccines provide parasite-derived antigens that are processed and presented as peptide-MHC complexes to activate specific TCRs, inducing protective memory. Checkpoint inhibitors block inhibitory receptors like PD-1 or LAG-3 on the T cell surface to enhance the effector function and longevity of the TCR-mediated immune response against the parasite.